Becton, Dickinson and Company $BDX Shares Newly Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 90,000 shares of the medical instruments supplier’s stock, valued at approximately $16,110,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $3,721,533,000. State Street Corp grew its holdings in Becton, Dickinson and Company by 8.5% during the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the period. First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after buying an additional 1,887,224 shares during the last quarter. Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the second quarter worth approximately $474,993,000. Finally, Legal & General Group Plc increased its position in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock worth $318,050,000 after buying an additional 30,766 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 6,907 shares of company stock valued at $1,269,128. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BDX. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. Wolfe Research began coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating for the company. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Piper Sandler increased their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $185.07.

Becton, Dickinson and Company Stock Down 0.4%

Becton, Dickinson and Company stock opened at $197.48 on Friday. The company’s 50-day moving average price is $186.58 and its two-hundred day moving average price is $170.26. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $54.41 billion, a P/E ratio of 59.48, a P/E/G ratio of 13.34 and a beta of 0.21. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.